Gram-negative sepsis: part II. Management.
D000138:Acidosis / Q000209:etiology; D000328:Adult; D000583:Amikacin / Q000627:therapeutic use; D002648:Child; D002701:Chloramphenicol / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004298:Dopamine / Q000627:therapeutic use; D005839:Gentamicins / Q000627:therapeutic use; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D007612:Kanamycin / Q000627:therapeutic use; D007674:Kidney Diseases / Q000209:etiology; D008680:Metaraminol / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D012131:Respiratory Insufficiency / Q000209:etiology; D018805:Sepsis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014031:Tobramycin / Q000627:therapeutic use
D005839:Gentamicins; D010643:Phenoxybenzamine; D002981:Clindamycin; D007612:Kanamycin; D002701:Chloramphenicol; D008680:Metaraminol; D000583:Amikacin; D007545:Isoproterenol; D004298:Dopamine; D014031:Tobramycin